New data from #WCN2026 highlight advances across kidney disease—from iptacopan in IgA nephropathy to semaglutide in CKD and emerging CAR-T approaches in lupus nephritis. Here are 5 key studies and insights shaping precision nephrology.
www.hcplive.com/view...
Did you know that the “four-hit” hypothesis for IgA nephropathy #IgAN was first clearly articulated by Hitoshi Suzuki et al. in their 2011 J. Am. Soc. Nephrol. paper, “The pathophysiology of IgA nephropathy.”
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/21949093/
Therapeutic targets 🎯and positioning of treatments in IgA nephropathy 🔬 #IgAN ca. 2026 from @kidneyint.bsky.social
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41895685/
This new article in #ASNJASN simultaneously published with #WCN2026 investigated the effect of empagliflozin, finerenone, and their combination on change from baseline in eGFR and its determinants, and the relationship of change in eGFR with albuminuria reduction. Read it here: kidney.pub/JASN1071
🌟 Enjoying our #WCN2026 coverage?
A heartfelt thank you to our incredible ISGD social media ambassadors, Dr. @gabyneph.bksy.social and Dr. Belén Gallegos, for bringing us the latest updates and insights in glomerular disease and keeping our community informed and engaged 🙌
#ISGD #GlomerularDisease
Efficacy and Safety of Atrasentan in Patients with #IgAN Receiving Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) ca. 2026 from @asnpublications.bsky.social
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
Photo Credit: @nephroseeker.medsky.social
👉 journals.lww.com/jasn/fulltex...
I made it to #ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 ... well, kinda ...
Photo Credit 👉 @hswapnil.medsky.social
pubmed.ncbi.nlm.nih.gov/35155869/
Trying to catch up with #IgAN trials⁉️
Check out 👉 “IgAN: An Overview of the Clinical Trials” ca. 2025 from @kidneymed.bsky.social @haresh11.bsky.social @alexgr23.bsky.social @saynanorouzi.bsky.social
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41050133/
SGLT2 inhibition: Pleiotropic direct cardiac and kidney effects ⁉️
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/35589167/
The draft of the @kdigo.org 2026 Clinical Practice Guideline for Acute Kidney Injury and Acute Kidney Disease is now available for public review through 🗓️ April 27, 2026
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉 kdigo.org/guidelines/a...
👉 FEEDBACK Form www.surveymonkey.com/r/GTGNFHG
Approach to immune checkpoint inhibitor (ICI) nephrotoxicity and rechallenge
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/32775813/
Diagnostic approach to hypophosphatemia
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/34754427/
Practical suggestions for the diagnosis and management of hypertension before, during, and after the start of anticancer therapy
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/36621810/
Cancer Therapy Related Hypertension
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/36621810/
Pathogenesis of IgA Nephropathy #IgAN
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/37742867/
Hypomagnesemia
📌 Manifestations and its association with cancer
📌 Causes in patients with cancer
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/37086496/
Individualized management of malignancy-associated hypercalcemia
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/41623290/
Pillars of IgA Nephropathy #IgAN Treatment
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉🏼 pubmed.ncbi.nlm.nih.gov/38398259/
Pillars of Treatment for Diabetic Kidney Disease secondary to Type 2 Diabetes (T2D)
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Nephpearls #NephSky
👉🏼 medicinetoday.com.au/mt/2024/dece...
An interactive, thought-provoking session at the Primer Course on Glomerular Diseases, Yokohama—learning from the best in the field.
@jonathanbarratt.bsky.social @adrianliew.bsky.social @heatherreich.bsky.social @suceenaalex.bsky.social @hernantrimarchi.bsky.social
#GlomerularDisease #WCN2026
Timely publication on "@asnkidney.bsky.social Kidney Health Guidance on Conservative Management in People with Kidney Failure" ca. 2026 from @asnpublications.bsky.social
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41848800/
Cardiovascular-Kidney-Metabolic (CKM) Syndrome Stages: Identify Chronic Kidney Disease (CKD) as an important risk ⚠️ for adverse outcomes
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 #Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/37807924/
If you're attending #WCN26 🇯🇵 #WCN2026 🇯🇵 do not miss @kdigo.org Guideline Education Meeting (GEM) #KDIGOGEMS 💎
#Nephpearls #NephSky
🗓️ Friday, March 27, 2026
⏰ 09:00 – 16:00 JST
📍 Room 303, Pacifico Yokohama Conference Center
Learn more: kdigo.co/WCN26-KDIGO-...
KDIGO Direct Newsletter Logo
Check out the latest issue of KDIGO Direct: kdigo.co/KDIGO-Direct...
In this issue:
- KDIGO at #WCN2026
- KDIGO starts update to CKD Guideline
- KDIGO Diabetes GL Draft available for review
- New Editorial on KDIGO Evolution
- KDIGO CKD & HF Conference Report
- Upcoming activities & new resources
In conjunction w/ @theisn.org
World Congress of Nephrology & Tokushukai Medical Group, @kdigo.org will host a full-day Guideline Education Meeting (GEM)
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵 #Nephpearls #KDIGOGEMS 💎 #NephSky
👉🏼 kdigo.org/events/kdigo...
